Detalles de la búsqueda
1.
Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Respir Res
; 20(1): 241, 2019 Oct 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-31666076
2.
Safety of bloodless autologous stem cell transplantation in Jehovah's Witness patients.
Bone Marrow Transplant
; 55(6): 1059-1067, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31898692
3.
Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease.
Data Brief
; 26: 104277, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31534988
4.
Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Respir Med
; 153: 38-43, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31150963
Resultados
1 -
4
de 4
1
Próxima >
>>